Mediwound Ltd Ord Sh (MDWD)

$17.19 +0.12 (0.70%)
Market Cap 189.26M
Revenue (ttm) 20.22M
Net Income (ttm) -30.22M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -149.46%
Debt to Equity Ratio 0.04
Volume 59,500
Avg Vol 109,504
Day's Range N/A - N/A
Shares Out 11.09M
Stochastic %K 17%
Beta 0.27
Analysts Strong Sell
Price Target $30.67

Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx for the treatment of chronic wounds and ot...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 7 797 14100
Fax: 972 7 797 14111
Address:
42 Hayarkon Street, Yavne, Israel
JohnPDaly
JohnPDaly Oct. 4 at 12:44 PM
$MDWD Getting in position to get into position.
0 · Reply
JohnPDaly
JohnPDaly Oct. 4 at 2:39 AM
Home - Access Industries $MDWD https://www.accessindustries.com/
0 · Reply
JohnPDaly
JohnPDaly Oct. 4 at 2:36 AM
SEC Filing | MediWound $MDWD https://ir.mediwound.com/node/11961/html
0 · Reply
novelty
novelty Oct. 3 at 5:54 PM
$MDWD 13$ is programmed in October
0 · Reply
novelty
novelty Oct. 3 at 5:51 PM
$MDWD now just think how bad this is gonna get once s&p500 rolls over 😂
0 · Reply
Logic102
Logic102 Oct. 3 at 5:27 PM
$MDWD From the article cited below: "MediWound's new state-of-the-art GMP manufacturing facility is on track for completion by year-end 2025, promising a six-fold increase in output. Regulatory approvals from the EMA are anticipated in the first half of 2026, followed by FDA approval in the second half of 2026, which will unlock significant revenue growth."
0 · Reply
novelty
novelty Oct. 3 at 5:07 PM
$MDWD where is zee contrarian pump team?
0 · Reply
novelty
novelty Oct. 3 at 5:06 PM
$MDWD just keep shorting 18 and u get rich. This pig going to 13
0 · Reply
novelty
novelty Oct. 3 at 3:50 PM
$MDWD 😂😂
0 · Reply
JohnPDaly
JohnPDaly Oct. 3 at 3:10 PM
MediWound's Enzymatic Edge: Unlocking Growth in Burn and Chronic Wound Care (NASDAQ:MDWD) - MDWD Analysis - BeyondSPX. $MDWD https://beyondspx.com/quote/MDWD/mediwound-s-enzymatic-edge-unlocking-growth-in-burn-and-chronic-wound-care-nasdaq-mdwd
0 · Reply
Latest News on MDWD
MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares

Sep 29, 2025, 8:37 AM EDT - 5 days ago

MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares

MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia

Sep 25, 2025, 7:30 AM EDT - 9 days ago

MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia

MediWound's NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress

Sep 2, 2025, 7:30 AM EDT - 4 weeks ago

MediWound's NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress

MediWound Is A Buy Opportunity On The Dip

Sep 2, 2025, 5:42 AM EDT - 4 weeks ago

MediWound Is A Buy Opportunity On The Dip

MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 20, 2025, 7:30 AM EDT - 6 weeks ago

MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference

MediWound Ltd. (MDWD) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 1:31 PM EDT - 7 weeks ago

MediWound Ltd. (MDWD) Q2 2025 Earnings Call Transcript

MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 7:00 AM EDT - 7 weeks ago

MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update

MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers

Aug 13, 2025, 8:45 AM EDT - 7 weeks ago

MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers

MediWound to Report Second Quarter 2025 Financial Results

Aug 4, 2025, 7:30 AM EDT - 2 months ago

MediWound to Report Second Quarter 2025 Financial Results

MediWound Ltd. (MDWD) Q1 2025 Earnings Call Transcript

May 21, 2025, 12:46 PM EDT - 4 months ago

MediWound Ltd. (MDWD) Q1 2025 Earnings Call Transcript

MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 21, 2025, 7:00 AM EDT - 4 months ago

MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update

MediWound Ltd.: Undervalued High-Growth Potential

May 16, 2025, 10:34 AM EDT - 5 months ago

MediWound Ltd.: Undervalued High-Growth Potential

MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers

May 13, 2025, 7:30 AM EDT - 5 months ago

MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers

MediWound to Report First Quarter 2025 Financial Results

May 5, 2025, 8:00 AM EDT - 5 months ago

MediWound to Report First Quarter 2025 Financial Results

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

Apr 28, 2025, 8:00 AM EDT - 5 months ago

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

MediWound Ltd. (MDWD) Q4 2024 Earnings Call Transcript

Mar 19, 2025, 12:10 PM EDT - 7 months ago

MediWound Ltd. (MDWD) Q4 2024 Earnings Call Transcript

MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 19, 2025, 7:00 AM EDT - 7 months ago

MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

MediWound to Report Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 8:00 AM EST - 7 months ago

MediWound to Report Fourth Quarter and Full Year 2024 Financial Results

MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care

Feb 25, 2025, 8:00 AM EST - 7 months ago

MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care

MediWound to Present at the 45th Annual TD Cowen Health Care Conference

Feb 24, 2025, 8:00 AM EST - 7 months ago

MediWound to Present at the 45th Annual TD Cowen Health Care Conference

MediWound to launch Phase III trial for venous leg ulcers

Feb 12, 2025, 8:12 AM EST - 8 months ago

MediWound to launch Phase III trial for venous leg ulcers

MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers

Feb 12, 2025, 7:00 AM EST - 8 months ago

MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers

MediWound Ltd. (MDWD) Q3 2024 Earnings Call Transcript

Nov 26, 2024, 1:46 PM EST - 11 months ago

MediWound Ltd. (MDWD) Q3 2024 Earnings Call Transcript

MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update

Nov 26, 2024, 7:00 AM EST - 11 months ago

MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update

MediWound Is A Healthy Investment

Oct 29, 2024, 10:49 AM EDT - 1 year ago

MediWound Is A Healthy Investment

MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers

Oct 10, 2024, 7:00 AM EDT - 1 year ago

MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers

MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns

Aug 15, 2024, 4:15 PM EDT - 1 year ago

MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns

MediWound Ltd. (MDWD) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 3:00 PM EDT - 1 year ago

MediWound Ltd. (MDWD) Q2 2024 Earnings Call Transcript

MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update

Aug 14, 2024, 7:00 AM EDT - 1 year ago

MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update

MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)

Aug 5, 2024, 7:30 AM EDT - 1 year ago

MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)

MediWound to Report Second Quarter 2024 Financial Results

Aug 2, 2024, 8:00 AM EDT - 1 year ago

MediWound to Report Second Quarter 2024 Financial Results

MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers

Jul 29, 2024, 8:00 AM EDT - 1 year ago

MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers

MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program

Jul 16, 2024, 7:30 AM EDT - 1 year ago

MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program

Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd

Jul 15, 2024, 7:32 AM EDT - 1 year ago

Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd

MediWound Announces $25 Million Strategic Private Placement Financing

Jul 15, 2024, 7:00 AM EDT - 1 year ago

MediWound Announces $25 Million Strategic Private Placement Financing

MediWound Ltd. (MDWD) Q1 2024 Earnings Call Transcript

May 29, 2024, 11:35 AM EDT - 1 year ago

MediWound Ltd. (MDWD) Q1 2024 Earnings Call Transcript

MediWound Reports First Quarter 2024 Financial Results and Provides Company Update

May 29, 2024, 7:00 AM EDT - 1 year ago

MediWound Reports First Quarter 2024 Financial Results and Provides Company Update

MediWound to Report First Quarter 2024 Financial Results

May 22, 2024, 8:00 AM EDT - 1 year ago

MediWound to Report First Quarter 2024 Financial Results

MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences

Apr 25, 2024, 8:00 AM EDT - 1 year ago

MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences

MediWound Ltd. (MDWD) Q4 2023 Earnings Call Transcript

Mar 21, 2024, 11:35 AM EDT - 1 year ago

MediWound Ltd. (MDWD) Q4 2023 Earnings Call Transcript

MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Mar 21, 2024, 7:00 AM EDT - 1 year ago

MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

MediWound to Report Fourth Quarter and Full Year 2023 Financial Results

Mar 14, 2024, 8:00 AM EDT - 1 year ago

MediWound to Report Fourth Quarter and Full Year 2023 Financial Results

MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study

Feb 12, 2024, 7:00 AM EST - 1 year ago

MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study

MediWound to Participate in Two Upcoming Investor Conferences

Feb 5, 2024, 8:00 AM EST - 1 year ago

MediWound to Participate in Two Upcoming Investor Conferences

MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns

Jan 9, 2024, 7:00 AM EST - 1 year ago

MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns

MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army

Dec 28, 2023, 7:00 AM EST - 1 year ago

MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army

MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads

Dec 21, 2023, 8:00 AM EST - 1 year ago

MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads

MediWound Ltd. (MDWD) Q3 2023 Earnings Call Transcript

Nov 21, 2023, 1:14 PM EST - 2 years ago

MediWound Ltd. (MDWD) Q3 2023 Earnings Call Transcript

MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update

Nov 21, 2023, 7:02 AM EST - 2 years ago

MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update

MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer

Nov 21, 2023, 7:00 AM EST - 2 years ago

MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer

JohnPDaly
JohnPDaly Oct. 4 at 12:44 PM
$MDWD Getting in position to get into position.
0 · Reply
JohnPDaly
JohnPDaly Oct. 4 at 2:39 AM
Home - Access Industries $MDWD https://www.accessindustries.com/
0 · Reply
JohnPDaly
JohnPDaly Oct. 4 at 2:36 AM
SEC Filing | MediWound $MDWD https://ir.mediwound.com/node/11961/html
0 · Reply
novelty
novelty Oct. 3 at 5:54 PM
$MDWD 13$ is programmed in October
0 · Reply
novelty
novelty Oct. 3 at 5:51 PM
$MDWD now just think how bad this is gonna get once s&p500 rolls over 😂
0 · Reply
Logic102
Logic102 Oct. 3 at 5:27 PM
$MDWD From the article cited below: "MediWound's new state-of-the-art GMP manufacturing facility is on track for completion by year-end 2025, promising a six-fold increase in output. Regulatory approvals from the EMA are anticipated in the first half of 2026, followed by FDA approval in the second half of 2026, which will unlock significant revenue growth."
0 · Reply
novelty
novelty Oct. 3 at 5:07 PM
$MDWD where is zee contrarian pump team?
0 · Reply
novelty
novelty Oct. 3 at 5:06 PM
$MDWD just keep shorting 18 and u get rich. This pig going to 13
0 · Reply
novelty
novelty Oct. 3 at 3:50 PM
$MDWD 😂😂
0 · Reply
JohnPDaly
JohnPDaly Oct. 3 at 3:10 PM
MediWound's Enzymatic Edge: Unlocking Growth in Burn and Chronic Wound Care (NASDAQ:MDWD) - MDWD Analysis - BeyondSPX. $MDWD https://beyondspx.com/quote/MDWD/mediwound-s-enzymatic-edge-unlocking-growth-in-burn-and-chronic-wound-care-nasdaq-mdwd
0 · Reply
JohnPDaly
JohnPDaly Oct. 3 at 3:05 PM
$MDWD https://x.com/yieldcurvebali/status/1973770476507086997?s=12
1 · Reply
novelty
novelty Oct. 3 at 2:53 PM
$MDWD 18$ the invincible resistance
0 · Reply
novelty
novelty Oct. 3 at 1:05 PM
$MDWD short this pig to 13
0 · Reply
SweepCastApp
SweepCastApp Oct. 2 at 3:42 PM
$MDWD: Unusual Options Activity Alerted CALL flow observed 50x contracts at Strike price of $14 Exp on 03/20/2026 with Premium of $27K and showing BULLISH Sentiment
0 · Reply
novelty
novelty Oct. 2 at 2:50 PM
$MDWD just know HCW has a huge short on this while recommending to clients as a screaming buy.
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 2 at 12:20 PM
$MDWD Excellent article that nails exactly where MDWD stands right now. So if you want to update your MDWD knowledge or get acquainted with MDWD, this is a must read. https://beyondspx.com/quote/MDWD/analysis/mediwound-s-enzymatic-edge-unlocking-growth-in-burn-and-chronic-wound-care-nasdaq-mdwd
2 · Reply
novelty
novelty Oct. 2 at 12:52 AM
$MDWD the funds supporting this are the ones shorting it hahaha
0 · Reply
wsrjeff
wsrjeff Oct. 1 at 8:13 PM
$MDWD Your risk in shorting MDWD is inverse. They now have a strong balance sheet and the support of some funds. They have a disruptive product that works. MDWD has been a thinly traded microcap without much support, and little IR. Your short strategy may have worked for a while, but if I were you, I would not sleep well. Catalysts coming.
0 · Reply
novelty
novelty Oct. 1 at 7:17 PM
$MDWD all u gotta do is short 18 every single time
0 · Reply
highnihilism
highnihilism Sep. 30 at 10:37 AM
$RLMD Relmada Therapeutics: 136 trades, $28K vs $6K avg (4.38x !!). $28K calls / $0 puts. $MDWD Mediwound: 9 trades, $28K vs $14K avg (1.98x). $28K calls / $0.4K puts. $NRP Natural Resources: 24 trades, $29K vs $26K avg (1.10x). $27K calls / $1K puts. $HOWL Werewolf Therapeutics: 63 trades, $30K vs $5K avg (6.04x !!). $27K calls / $3K puts.
0 · Reply
JohnPDaly
JohnPDaly Sep. 29 at 5:18 PM
$LCTX $MDWD $BTC.X All of humanity's problems stem from man's inability to sit quietly in a room alone.- Blaise Pascal, Pensées
1 · Reply
_www_larval_com_
_www_larval_com_ Sep. 29 at 1:48 PM
$MDWD has soared 8% higher to 0% (~19Kv) a few minutes ago, 10/17 options, follow for more volatility.
0 · Reply